National Institute of Pharmacy and Nutrition

CERTIFICATE NUMBER: OGYÉI/53685-6/2019

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with:

The competent authority of Hungary confirms the following:

The manufacturer: MSN LABORATORIES PRIVATE LIMITED FORMULATIONS DIVISION UNIT II
Site address: SURVEY NOS. 1277 & 1319 TO 1324, NANDIGAMA VILLAGE & MANDAL, RANGA
REDDY DISTRICT, TELANGANA, 509228, India

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 111(4) of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2019-12-19, it is considered that it complies with:

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

Issuance Date 2020-02-14 Signatory: Confidential

¹The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

 $^{^2}$ Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³These requirements fulfil the GMP recommendations of WHO.

Part 2

1 MANUFACTURING OPERATIONS	
1.2	Non-sterile products
	1.2.1 Non-sterile products (processing operations for the following dosage forms)
	1.2.1.1 Capsules, hard shell
	1.2.1.13 Tablets
1.5	Packaging
	1.5.1 Primary Packaging
	1.5.1.1 Capsules, hard shell
	1.5.1.13 Tablets
	1.5.2 Secondary packaging
1.6	Quality control testing
	1.6.2 Microbiological: non-sterility
	1.6.3 Chemical/Physical

Clarifying remarks (for public users)

The inspection covered the manufacturing of oncological oral solid dosage products in Block C and general oral solid dosage products in Block D.

2020-02-14

Name and signature of the authorised person of the Competent Authority of Hungary

Confidential

National Institute of Pharmacy and Nutrition
Tel:Confidential
Fax:Confidential